FDA drug-plant inspections still haven't recovered from the pandemic, AP reports

Since the COVID-19 pandemic began, the FDA has failed to inspect around 2,000 drug manufacturing plants, creating a backlog that compromises patient safety.

Around 42% of registered drug manufacturers in the U.S. haven't been inspected since before the pandemic, putting critical medication supplies at risk.

The FDA claims that U.S. drug supply is 'the safest on the planet,' but significant inspection lapses raise concerns about the true state of drug safety.

Despite ramping up inspections in 2021, the FDA's workload from the pandemic still hinders its ability to ensure timely inspections for critical drug facilities.

Read at Fast Company